HCV genotype-3a T cell immunity: specificity, function and impact of therapy

Area of Science:

• Immunology
• Virology
• Hepatology

Background:

• Hepatitis C virus (HCV) genotype-3a is prevalent in South Asia and the UK.
• HCV genotype-3a typically responds well to therapy, but the underlying immunological reasons are unclear.
• T cell immunity in HCV genotype-3a is less understood compared to genotype-1.

Purpose of the Study:

• To characterize T cell immunity across the viral genome in HCV genotype-3a infection.
• To investigate the specificity and cross-reactivity of T cell responses in genotype-3a.
• To evaluate the effect of interferon (IFN)-α/ribavirin therapy on T cell immunity.

Main Methods:

• Analysis of T cell responses in chronic and resolved HCV genotype-3a infections compared to genotype-1.
• Utilized IFN-γ ELISpot assays with specific peptide panels.
• Longitudinal monitoring of T cell responses during therapy, including CD4/CD8 subset analysis and viral sequencing.

Main Results:

• CD8 T cell responses targeted non-structural (NS) proteins in chronic genotype-3a, unlike genotype-1 where CD4 responses to core protein predominated.
• Resolved infection correlated with CD4 T cells targeting NS proteins.
• Therapy response was paradoxically linked to a temporary decline in virus-specific lymphocytes.

Conclusions:

• HCV genotype-3a displays distinct T cell specificities, relevant for vaccine development.
• Enhanced antiviral T cell response does not appear to drive genotype-3a clearance during therapy.
• Reduced T cell responses during treatment may serve as a biomarker for IFN responsiveness in HCV genotype-3a.